a Oncology Department, Department of Therapeutics, Alexandra Hospital , National and Kapodistrian University of Athens , Athens , Greece.
Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18.
B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells. Serum BCMA is elevated in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and might represent a novel prognostic and monitoring tool. Serum BCMA levels can predict both progression free survival (PFS) and overall survival (OS). Several therapeutic strategies are currently under investigation including BCMA-directed monoclonal Abs (either naked or with drug conjugates, and bispecific Abs) and cellular T-cell therapies (chimeric antigen receptor T-cells) with impressive clinical results. Areas covered: This review aims to present the mechanisms of action and the available data on efficacy and safety of therapies targeting BCMA. Expert opinion: The preliminary preclinical and clinical results from the phase 1 and 2 studies have demonstrated significant activity of the anti-BCMA therapeutic strategies. The main toxicities induced include Cytokine Release Syndrome (CRS) and ocular toxicity. The management of these adverse events remains currently an issue of controversy.
B 细胞成熟抗原 (BCMA) 属于肿瘤坏死因子受体家族，在晚期 B 细胞和浆细胞上表达。多发性骨髓瘤 (MM) 和慢性淋巴细胞白血病 (CLL) 患者的血清 BCMA 水平升高，可能代表一种新的预后和监测工具。血清 BCMA 水平可预测无进展生存期 (PFS) 和总生存期 (OS)。目前正在研究几种治疗策略，包括针对 BCMA 的单克隆抗体（无论是裸抗体还是与药物偶联物和双特异性抗体）和细胞 T 细胞疗法（嵌合抗原受体 T 细胞），这些疗法取得了令人印象深刻的临床结果。
本综述旨在介绍针对 BCMA 的作用机制以及现有疗效和安全性数据。
来自 1 期和 2 期研究的初步临床前和临床结果表明，抗 BCMA 治疗策略具有显著的活性。诱导的主要毒性包括细胞因子释放综合征 (CRS) 和眼毒性。目前，这些不良反应的管理仍然是一个有争议的问题。
